| Literature DB >> 26000323 |
Chih-Ping Chung1, Chin-Sern Yong2, Feng-Chi Chang3, Wen-Yung Sheng2, Hui-Chi Huang4, Jui-Yao Tsai4, Hung-Yi Hsu5, Han-Hwa Hu1.
Abstract
OBJECTIVE: Stroke research and clinical trials have focused mainly on anterior circulation stroke (ACS). Since clinical characteristics, mechanisms, and outcomes of posterior circulation stroke (PCS) have been reported different from ACS, more PCS studies are required, particularly researching the etiologies, to help establish an optimal management strategy.Entities:
Year: 2015 PMID: 26000323 PMCID: PMC4435705 DOI: 10.1002/acn3.188
Source DB: PubMed Journal: Ann Clin Transl Neurol ISSN: 2328-9503 Impact factor: 4.511
Demographic, clinical characteristics, and outcomes comparisons among five patient groups with different etiologies of posterior circulation ischemic strokes (total population = 286)
| BABO ( | LAA ( | LAD ( | CE ( | SVD ( |
| |
|---|---|---|---|---|---|---|
| Age, years | 73.3 (11.0) | 74.7 (10.1) | 65.8 (15.6) | 73.4 (13.8) | 70.1 (15.2) | 0.007 |
| Gender, men | 54 (67.5%) | 40 (67.8%) | 56 (75.7%) | 30 (56.6%) | 17 (85%) | 0.097 |
| Risk factors | ||||||
| Hypertension | 63 (78.8%) | 52 (88.1%) | 57 (77.0%) | 37 (69.8%) | 14 (70.0%) | 0.171 |
| Diabetes | 42 (52.5%) | 29 (49.2%) | 34 (45.9%) | 17 (32.1%) | 7 (35.0%) | 0.156 |
| Hyperlipidemia | 24 (30.0%) | 20 (33.9%) | 26 (35.1%) | 19 (35.8%) | 4 (20.0%) | 0.700 |
| Atrial fibrillation | 4 (5.0%) | 2 (3.3%) | 5 (6.8%) | 26 (49.1%) | 1 (5.0%) | <0.0001 |
| Smoking | 11 (13.8%) | 10 (16.9%) | 22 (29.7%) | 9 (17.0%) | 4 (20.0%) | 0.350 |
| Cerebral infarct | ||||||
| Location | ||||||
| Distal | 4 (5.0%) | 17 (28.8%) | 19 (25.7%) | 43 (81.1%) | 12 (60%) | <0.0001 |
| Middle | 72 (90%) | 37 (62.7%) | 47 (63.5%) | 14 (26.4%) | 7 (35.0%) | <0.0001 |
| Proximal | 8 (10%) | 16 (27.1%) | 27 (36.5%) | 10 (18.9%) | 1 (5.0%) | 0.0004 |
| Lesion | ||||||
| Inclusive | 4 (5%) | 13 (22%) | 16 (21.6%) | 13 (24.5%) | 0 | 0.0015 |
| Admission NIHSS | 4.6 (3.2) | 5.9 (6.0) | 6.9 (8.3) | 6.6 (8.3) | 3.6 (3.7) | 0.320 |
| Treatments | ||||||
| i.v. tPA | 1 (1.3%) | 0 | 0 | 1 (1.9%) | 0 | 0.644 |
| Antiplatelets | 80 (100%) | 59 (100%) | 74 (100%) | 53 (100%) | 20 (100%) | - |
| Anticoagulants | 3 (3.8%) | 10 (16.9%) | 22 (29.7%) | 12 (22.6%) | 0 | <0.0001 |
| Stenting | 0 | 3 (5.1%) | 3 (4.1%) | 0 | 0 | 0.125 |
| Outcomes | ||||||
| Discharge | ||||||
| Mortality | 1 (1.3%) | 4 (6.8%) | 5 (6.8%) | 0 | 0 | 0.090 |
| mRS | 3.1 (1.1) | 3.4 (1.5) | 3.0 (1.7) | 3.1 (1.5) | 2.3 (1.3) | 0.044 |
| 3 month | ||||||
| mRS | 2.2 (1.6) | 2.4 (1.9) | 2.1 (1.8) | 2.6 (2.1) | 1.3 (1.6) | 0.065 |
Presented as means (SD) or number (percentage). BABO, basilar artery atheromatous branch occlusive disease; LAA, large artery atherosclerotic stenosis/occlusion; LAD, large artery dissection; CE, cardioembolism; SVD, small vessel disease; NIHSS, National Institute of Health stroke scale; tPA, tissue plasminogen activator; mRS, modified Rankin Scale.
P value of post hoc test <0.005 versus BABO, LAA, and CE respectively.
Oral medicines.
Excluding mortality at discharge.
Predictors of poor functional outcome with modified Rankin Scale ≥5 at discharge
| Characteristics | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| OR (95% CI) |
| OR (95% CI) |
| |
| Age, > vs. ≤70 years | 3.57 (1.66–7.65) | 0.0006 | 3.05 (1.23–7.56) | 0.016 |
| NIHSS, > vs. ≤9 | 19.65 (9.43–40.94) | <0.0001 | 19.50 (8.69–43.75) | <0.0001 |
| Atrial fibrillation | 2.40 (1.12–5.15) | 0.022 | ||
| Hyperlipidemia | 0.43 (0.21–0.91) | 0.024 | ||
| Infarct location, upper | 2.36 (1.28–4.36) | 0.005 | ||
| Inclusive vs. single lesion | 3.84 (1.92–7.69) | <0.0001 | ||
| Etiology, vs. BABO | ||||
| LAA | 3.88 (1.48–10.18) | 0.006 | 5.00 (1.58–15.83) | 0.006 |
| LAD | 2.43 (0.92–6.42) | 0.072 | 1.97 (0.61–6.39) | 0.259 |
| CE | 3.74 (1.40–10.05) | 0.009 | 3.36 (1.02–11.09) | 0.046 |
| SVD | 0.55 (0.06–4.74) | 0.585 | 0.87 (0.08–9.73) | 0.907 |
OR, odds ratio; CI, confidence interval; NIHSS, National Institute of Health stroke scale; BABO, basilar artery atheromatous branch occlusive disease; LAA, large artery atherosclerotic stenosis/occlusion; LAD, large artery dissection; CE, cardioembolism; SVD, small vessel disease.
Only listing variables with statistically significance at univariate analysis.
Predictors of poor functional outcome with modified Rankin Scale ≥5 at 3 month
| Characteristics | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| OR (95% CI) |
| OR (95% CI) |
| |
| Age, > vs. ≤70 years | 10.05 (3.02–33.43) | <0.0001 | 8.39 (2.32–30.33) | 0.001 |
| NIHSS, > vs. ≤9 | 13.52 (6.34–28.86) | <0.0001 | 13.45 (5.59–32.39) | <0.0001 |
| Atrial fibrillation | 2.84 (1.28–6.32) | 0.008 | ||
| Infarct location, upper | 2.10 (1.08–4.10) | 0.027 | ||
| Inclusive vs. single lesion | 3.48 (1.64–7.38) | 0.0007 | ||
| Etiology, vs. BABO | ||||
| LAA | 3.40 (1.19–9.70) | 0.023 | 4.00 (1.19–13.41) | 0.025 |
| LAD | 1.37 (0.44–4.30) | 0.586 | 1.14 (0.30–4.27) | 0.851 |
| CE | 4.80 (1.72–13.38) | 0.003 | 4.66 (1.40–15.46) | 0.012 |
| SVD | 1.35 (0.25–7.26) | 0.725 | 2.49 (0.37–16.85) | 0.349 |
Excluding mortality at discharge when analyzing. OR, odds ratio; CI, confidence interval; BABO, basilar artery atheromatous branch occlusive disease; LAA, large artery atherosclerotic stenosis/occlusion; LAD, large artery dissection; CE, cardioembolism; SVD, small vessel disease; NIHSS, National Institute of Health stroke scale.
Only listing variables with statistically significance at univariate analysis.
Stroke etiologies in other stroke registries
| TVGHSR ( | HSR ( | NEMC ( | LSR ( | ASR ( | |
|---|---|---|---|---|---|
| Years | 2012–2014 | 1996–2002 | 1988–1996 | 1982–1987 | 1992–1997 |
| LAA | 20% | 50% | 31% | 16% | 16% |
| Arterial dissection | 25% | <2% | 1% | 9% | <2% |
| Cardioembolism | 18% | 5% | 24% | 16% | 23% |
| Penetrating artery | 34% | 14% | 16% | 23% | |
| SVD | 7% | ||||
| BABO | 27% | ||||
| Undetermined | 4% | 9% | 3% | 14% | 26% |
TVGHSR, Taipei Veterans General Hospital Stroke Registry; HSR, Hallym Stroke Registry in Korea; NEMC, New England Medical Center; LSR, Lausanne Stroke Registry; ASR, Athens Stroke Registry; BABO, basilar artery atheromatous branch occlusive disease; LAA, large artery atherosclerotic stenosis/occlusion; SVD, small vessel disease.
Patients with undetermined etiology was included for comparisons with the other registries.
Arterial dissection was included in the category of “other stroke etiology”. Explicit number of patients with arterial dissection was not mentioned.
BABO was not differentiated from SVD in other stroke registries.